Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10195437rdf:typepubmed:Citationlld:pubmed
pubmed-article:10195437lifeskim:mentionsumls-concept:C0009521lld:lifeskim
pubmed-article:10195437lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:10195437lifeskim:mentionsumls-concept:C0056196lld:lifeskim
pubmed-article:10195437lifeskim:mentionsumls-concept:C1824180lld:lifeskim
pubmed-article:10195437lifeskim:mentionsumls-concept:C0597358lld:lifeskim
pubmed-article:10195437lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:10195437pubmed:issue1lld:pubmed
pubmed-article:10195437pubmed:dateCreated1999-6-10lld:pubmed
pubmed-article:10195437pubmed:abstractTextThe potent, conformationally biased C5a agonist peptide YSFKPMPLaR (C5a65-74, Y65, F67, P69, P71, D-Ala73) was used as a template to gain insight into the nature and importance of lysine at position 68 in the peptide-receptor interaction. A panel of YSFKPMPLaR analogs with systematic substitutions for Lys68 was evaluated for C5a receptor (C5aR) binding affinity and activation in two well-characterized assay systems: human polymorphonuclear leukocytes (PMNs) and human fetal artery. In addition, we determined the activity of these new analogs in transfected rat basophilic leukemia (RBL) cells in which the Glu at position 199 of the C5aR (wtGlu199) was replaced by a Gln (C5aR-Gln199) or a Lys (C5aR-Lys199). Our results indicated that Lys68 in YSFKPMPLaR plays an important role in binding the C5aR expressed on PMNs and RBL cells. Furthermore, the data indicated that Lys68 interacted with Glu199 of the C5aR in PMNs and RBL cells. In human fetal artery, however, Lys68 substitutions had little or no effect on activity, which suggested that the receptor conformation may be different in this tissue. Thus, the interaction between Lys68 of the decapeptide agonist and Glu199 of the C5aR may be cell type-specific and may form the molecular basis for tissue-specific responses to C5a agonists.lld:pubmed
pubmed-article:10195437pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:languageenglld:pubmed
pubmed-article:10195437pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:citationSubsetIMlld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10195437pubmed:statusMEDLINElld:pubmed
pubmed-article:10195437pubmed:monthJanlld:pubmed
pubmed-article:10195437pubmed:issn1397-002Xlld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:ThatcherJJlld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:TaylorS MSMlld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:SandersonS...lld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:MonkP NPNlld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:FinchA MAMlld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:VogenS MSMlld:pubmed
pubmed-article:10195437pubmed:authorpubmed-author:WadiS KSKlld:pubmed
pubmed-article:10195437pubmed:issnTypePrintlld:pubmed
pubmed-article:10195437pubmed:volume53lld:pubmed
pubmed-article:10195437pubmed:ownerNLMlld:pubmed
pubmed-article:10195437pubmed:authorsCompleteYlld:pubmed
pubmed-article:10195437pubmed:pagination8-17lld:pubmed
pubmed-article:10195437pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:meshHeadingpubmed-meshheading:10195437...lld:pubmed
pubmed-article:10195437pubmed:year1999lld:pubmed
pubmed-article:10195437pubmed:articleTitleThe influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivity.lld:pubmed
pubmed-article:10195437pubmed:affiliationEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha 68198-6805, USA.lld:pubmed
pubmed-article:10195437pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10195437pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10195437pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed